Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance Revenue and Adjusted EBITDA results delivered in line with stated full-year targets Full‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full year Fourth-quarter book-to-bill ratio of 1.14x,

#FTRE Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

www.stocktitan.net/news/FTRE/fortrea-report...

SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery SCTbio and Fortrea (FTRE) announced a strategic collaboration on December 4, 2025 to align CDMO manufacturing and CRO clinical development for cell and gene therapies. The partnership aims to streamline development timelines, harmonize GMP manufacturing readiness with trial logistics, and reduce program risk by enabling early protocol alignment, supply‑chain resilience, and coordinated planning from first‑in‑human trials toward commercialization.The agreement stresses synchronized execution across manufacturing, apheresis, viral vectors and global clinical operations to accelerate delivery of advanced therapies to patients.

#FTRE SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery

www.stocktitan.net/news/FTRE/sc-tbio-and-fo...

#FTRE Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand

www.stocktitan.net/news/FTRE/fortrea-comple...

Fortrea Reports Third Quarter 2025 Results Fortrea (Nasdaq: FTRE) reported third-quarter 2025 continuing-operations results with Q3 revenue of $701.3M and a Q3 adjusted EBITDA of $50.7M. GAAP net loss for the quarter was $15.9M and adjusted net income was $11.7M (diluted EPS $0.12). Backlog stood at $7,644M and book-to-bill was 1.13x. Year-to-date revenue was $2,062.9M, while YTD GAAP net loss was $953.7M, which included a $797.9M non-cash goodwill impairment impacting EPS by $8.81. The company raised full-year 2025 revenue guidance to $2,700M–$2,750M and narrowed adjusted EBITDA guidance to $175M–$195M.Management said cost-saving initiatives remain on track and there were no impairment indicators in Q3.

#FTRE Fortrea Reports Third Quarter 2025 Results

www.stocktitan.net/news/FTRE/fortrea-report...

Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt Fortrea (Nasdaq: FTRE) commenced a cash tender offer to purchase up to $75,744,000 aggregate principal of its outstanding 7.500% Senior Secured Notes due 2030, effective October 20, 2025. The offer price is $1,000 per $1,000 principal plus accrued interest; the Tender Offer will expire at 5:00 p.m. New York time on November 18, 2025 unless extended.The principal purpose is to comply with indenture covenants tied to net proceeds from Fortrea’s June 2024 divestiture; funding is expected from cash on hand and/or other liquidity sources. Acceptance is subject to conditions and possible proration. Holders may withdraw tenders prior to expiration.

#FTRE Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt

www.stocktitan.net/news/FTRE/fortrea-announ...

FTRE Shareholders Invited to Take Action Against Fortrea Holdings Securities Misconduct Shareholders of Fortrea Holdings, Inc. are encouraged to join a class action lawsuit due to alleged securities law violations. Key details and deadlines are provided.

FTRE Shareholders Invited to Take Action Against Fortrea Holdings Securities Misconduct #United_States #Fortrea_Holdings #DJS_Law_Group #Eastchester #FTRE

Fortrea Holdings Inc. Shareholders Alerted About Class Action Lawsuit and Participation Deadlines Fortrea Holdings Inc. investors are warned about a class action lawsuit and a looming deadline to register. Act now to protect your interests.

Fortrea Holdings Inc. Shareholders Alerted About Class Action Lawsuit and Participation Deadlines #United_States #New_York #Gross_Law_Firm #Fortrea_Holdings #FTRE

FTRE Shareholders Encouraged to Lead Lawsuit Against Fortrea Holdings Amid Securities Violations Investors in Fortrea Holdings, Inc. are urged to contact DJS Law Group about a class action lawsuit for securities law violations. Don't miss the deadline!

FTRE Shareholders Encouraged to Lead Lawsuit Against Fortrea Holdings Amid Securities Violations #USA #Los_Angeles #Fortrea_Holdings #DJS_Law_Group #FTRE

Important Shareholder Update: Fortrea Holdings Inc. Lawsuit and Lead Plaintiff Deadline Fortrea Holdings Inc. shareholders are notified about the upcoming deadline for lead plaintiff designation in their class action lawsuit set for August 1, 2025.

Important Shareholder Update: Fortrea Holdings Inc. Lawsuit and Lead Plaintiff Deadline #United_States #New_York #Gross_Law_Firm #Fortrea_Holdings #FTRE

Investors Invited to Join Securities Class Action Against Fortrea Holdings, Inc. The DJS Law Group has announced a class action lawsuit against Fortrea Holdings, Inc. for federal securities law violations. Shareholders are urged to contact the firm before August 1, 2025.

Investors Invited to Join Securities Class Action Against Fortrea Holdings, Inc. #United_States #Fortrea_Holdings #DJS_Law_Group #Eastchester #FTRE

Fortrea Holdings, Inc. Shareholders Are Invited to Participate in Potential Class Action Lawsuit Fortrea Holdings, Inc. faces legal action for alleged violations of securities laws. Shareholders are encouraged to join before the deadline.

Fortrea Holdings, Inc. Shareholders Are Invited to Participate in Potential Class Action Lawsuit #USA #Los_Angeles #DJS_Law_Group #FTRE #Fortrea

Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO),

#FTRE Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin

www.stocktitan.net/news/FTRE/fortrea-emery-...

Deadline Approaches for Class Action Against Fortrea Holdings Inc. Investors Investors in Fortrea Holdings Inc. should note the approaching August 1, 2025 deadline to join a class action lawsuit over alleged securities fraud.

Deadline Approaches for Class Action Against Fortrea Holdings Inc. Investors #USA #New_York #Levi_&_Korsinsky #Fortrea_Holdings #FTRE

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CYTK, #HCAT, #WGS, #FTRE, #DAR

#OptionFlow #OptionsTrading #Trading

Fortrea Activates Poison Pill Strategy After Third-Party Interest Sparks Takeover Concerns CRO giant adopts stockholder rights plan with 10% trigger threshold to protect against hostile takeovers amid stock price volatility. See defense details.

#FTRE Fortrea Adopts Limited-Duration Stockholder Rights Plan

www.stocktitan.net/news/FTRE/fortrea-adopts...

Fortrea Taps 20-Year Life Sciences Leader Anshul Thakral as CEO to Drive Transformation Strategy Life sciences executive Anshul Thakral to lead Fortrea's transformation plan and growth strategy. Learn how his 20-year industry expertise will reshape the CRO giant. See details.

#FTRE Fortrea Names Anshul Thakral Chief Executive Officer

www.stocktitan.net/news/FTRE/fortrea-names-...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue May 20th - #WULF #NRXS #RIG #TDOC #SYTA #QUBT #QMCO #NVAX #MGNX #LEU #KULR #IQ #HUT #FTRE #ESPR #DAWN #CGC #CERS #ATER #ASST - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Fortrea Reports First Quarter 2025 Results Fortrea (FTRE) reported its Q1 2025 financial results, showing revenues of $651.3 million, down from $662.1 million in Q1 2024. The company posted a significant GAAP net loss of $(562.9) million, largely due to a non-cash goodwill impairment charge of $488.8 million. Adjusted EBITDA improved to $30.3 million from $27.1 million year-over-year.The company maintained a positive book-to-bill ratio of 1.02x for the quarter and 1.14x for trailing 12 months, with a backlog of $7,721 million. Fortrea reaffirmed its 2025 guidance, projecting revenues of $2,450-$2,550 million and adjusted EBITDA of $170-200 million. Additionally, the company announced a leadership change, with Lead Independent Director Peter M. Neupert replacing Thomas Pike as Interim CEO and Board Chair effective May 13, 2025.

#FTRE Fortrea Reports First Quarter 2025 Results

www.stocktitan.net/news/FTRE/fortrea-report...

Fortrea Announces CEO Stepping Down Fortrea (FTRE) announced that CEO Thomas Pike is stepping down from his role as Chief Executive Officer and Chairman of the Board, effective May 13, 2025. Peter M. Neupert, the company's Lead Independent Director, will serve as Interim CEO and Board Chair. The company has already initiated an executive search process at an advanced stage, and Pike will remain as a consultant during the transition period.Neupert brings significant healthcare and technology industry experience, having served as an Operating Partner at Health Evolution Partners and Corporate Vice President at Microsoft's Health Solutions Group. The leadership change comes as Fortrea approaches its two-year anniversary as an independent contract research organization (CRO).The company will hold its earnings conference call on May 12, 2025, at 9 a.m. ET.

#FTRE Fortrea Announces CEO Stepping Down

www.stocktitan.net/news/FTRE/fortrea-announ...

Pomerantz Law Firm Launches Investigation into Fortrea Holdings Investors' Claims Pomerantz LLP is conducting an investigation related to potential securities fraud claims involving Fortrea Holdings Inc., following a significant stock price drop.

Pomerantz Law Firm Launches Investigation into Fortrea Holdings Investors' Claims #United_States #New_York #Pomerantz_LLP #Fortrea_Holdings #FTRE

Fortrea Holdings Inc. Investor Claims Under Investigation by Pomerantz Law Firm Investors of Fortrea Holdings Inc. are being urged by Pomerantz Law Firm to explore potential claims amid concerning financial disclosures and stock price drops.

Fortrea Holdings Inc. Investor Claims Under Investigation by Pomerantz Law Firm #United_States #New_York #Pomerantz_Law #Fortrea_Holdings #FTRE

Investors Under Scrutiny: Pomerantz Law Firm Investigates Fortrea Holdings Inc. for Potential Fraud Pomerantz Law Firm is probing claims from Fortrea Holdings Inc. investors regarding potential securities fraud and negative financial disclosures.

Investors Under Scrutiny: Pomerantz Law Firm Investigates Fortrea Holdings Inc. for Potential Fraud #None #Pomerantz_LLP #Fortrea_Holdings #FTRE

Fortrea Reports Fourth Quarter and Full-Year 2024 Results; Issues Full-Year 2025 Guidance Fortrea (FTRE) has released its Q4 and full-year 2024 financial results, reporting Q4 revenue of $697.0 million and full-year revenue of $2,696.4 million. The company posted a Q4 GAAP net loss of $(73.9) million and full-year net loss of $(271.5) million.Key highlights include:Q4 book-to-bill ratio of 1.35x, with trailing twelve-month ratio at 1.16xQ4 adjusted EBITDA of $56.0 million; full-year adjusted EBITDA of $202.5 millionBacklog of $7,699 million as of December 31, 2024Cash position of $118.5 million with gross debt of $1,142.0 millionFor 2025, Fortrea projects revenue between $2,450-2,550 million and adjusted EBITDA of $170-200 million. The company has also secured a credit agreement amendment providing additional financial covenant flexibility through Q4 2026.

#FTRE Fortrea Reports Fourth Quarter and Full-Year 2024 Results; Issues Full-Year 2025 Guidance

www.stocktitan.net/news/FTRE/fortrea-report...

Can This New Clinical Research Alliance Revolutionize Drug Trial Speed? Strategic partnership aims to reduce administrative burdens and enhance trial efficiency through collaboration with 16 leading research organizations.

#FTRE Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research

www.stocktitan.net/news/FTRE/society-for-cl...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Thu Feb 6th - #AMS #TCMD #ATSG #PET #BGM #NVAX #CNCK #FTRE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Pomerantz Law Firm Investigates Securities Fraud Claims Against Fortrea Holdings Inc. Pomerantz LLP is looking into claims of securities fraud by Fortrea Holdings, following recent stock downgrades and price drops.

Pomerantz Law Firm Investigates Securities Fraud Claims Against Fortrea Holdings Inc. #United_States #New_York #Pomerantz_LLP #Fortrea_Holdings #FTRE

Fortrea Earnings Watch: What Q4 Results Mean for CRO Industry Growth Fortrea schedules Q4 and FY2024 earnings release and conference call for March 3, 2025. Management to discuss financial performance and industry outlook at 9:00 AM ET.

#FTRE Fortrea Announces Date for Fourth Quarter and Full Year 2024 Financial Results and Conference Call

www.stocktitan.net/news/FTRE/fortrea-announ...

Pomerantz Law Firm Investigates Fortrea Holdings Amid Concerns Over Securities Fraud Pomerantz Law Firm is exploring potential claims related to investor losses at Fortrea Holdings. Concerns center on securities fraud allegations and company operations.

Pomerantz Law Firm Investigates Fortrea Holdings Amid Concerns Over Securities Fraud #United_States #New_York #Pomerantz_Law_Firm #Fortrea_Holdings #FTRE